G H Fromm, C F Terrence, A S Chattha
Index: Epilepsia 24(4) , 394-400, (1983)
Full Text: HTML
The effect of the experimental anticonvulsant cinromide (3-bromo-N-ethylcinnamamide) on various inhibitory and excitatory mechanisms was investigated in the trigeminal nucleus of cats. Intravenous administration of 20-80 mg/kg cinromide depressed excitatory transmission and facilitated segmental inhibition to the same extent as phenytoin, but less than carbamazepine. These doses of cinromide also depressed periventricular inhibition, similar to valproate and ethosuximide. In addition, cinromide had a marked depressant effect on the EEG, suggesting a pronounced sedative effect. The serum levels of cinromide and of its active metabolites (3-bromocinnamamide and 3-bromocinnamic acid) were comparable to those in patients receiving long-term treatment with cinromide. Our results agree with those in other experimental models, which also suggest that cinromide is a broad-spectrum anticonvulsant, and with cinromide's effect in the clinical trials reported so far.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
Cinromide
CAS:58473-74-8 |
C11H12BrNO |
Prediction of steady-state behavior of metabolite from dosin...
1980-05-01 [J. Pharm. Sci. 69(5) , 610-2, (1980)] |
Variability in the determination of fraction metabolized in ...
1984-02-01 [J. Pharm. Sci. 73(2) , 285-7, (1984)] |
Simultaneous determination of the anticonvulsants, cinromide...
[J. Chromatogr. A. 163(2) , 187-93, (1979)] |
The effect of cinromide on "kindled" seizures in the rat.
1982-03-01 [Neuropharmacology 21(3) , 273-6, (1982)] |
Double-blind, placebo-controlled evaluation of cinromide in ...
1989-01-01 [Epilepsia 30(4) , 422-9, (1989)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved